Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings

Vertex Pharmaceuticals (VRTX) is set to report its fourth-quarter 2024 earnings on February 10, and investors are eagerly awaiting the company's key drivers and future prospects. Top Wall Street forecasters have recently revised their price expectations for Vertex's stock, reflecting a positive market sentiment towards the company's Q4 earnings and long-term growth potential. Here's a closer look at the revised price targets and the factors driving the upward revision.